Cargando…
Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis
BACKGROUND: Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ∼10–15 years before the resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and predict dementia onset would, therefore, be invaluable f...
Autores principales: | Craig-Schapiro, Rebecca, Kuhn, Max, Xiong, Chengjie, Pickering, Eve H., Liu, Jingxia, Misko, Thomas P., Perrin, Richard J., Bales, Kelly R., Soares, Holly, Fagan, Anne M., Holtzman, David M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079734/ https://www.ncbi.nlm.nih.gov/pubmed/21526197 http://dx.doi.org/10.1371/journal.pone.0018850 |
Ejemplares similares
-
Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation
por: Kauwe, John S. K., et al.
Publicado: (2014) -
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
por: Whelan, Christopher D., et al.
Publicado: (2019) -
Multiplex Immunoassays: Chips and Beads
por: Vostrý, Michal
Publicado: (2010) -
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
por: Brier, Matthew R., et al.
Publicado: (2016) -
Diurnal oscillation of CSF Aβ and other AD biomarkers
por: Lucey, Brendan P., et al.
Publicado: (2017)